Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 1
2004 1
2005 1
2008 1
2012 1
2014 1
2015 2
2018 1
2019 2
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Zlotnick M, Avigdor A, Ribakovsky E, Nagler A, Kedmi M. Zlotnick M, et al. Acta Haematol. 2019;141(2):84-90. doi: 10.1159/000495283. Epub 2019 Jan 10. Acta Haematol. 2019. PMID: 30630175
Relapsed vs. refractory disease, as well as a response to gemcitabine, predicted better PFS and OS. Use of a full-dose regimen predicted a better OS. Compared to previously published data, we observed less favorable outcomes. The administration of gemcitabine …
Relapsed vs. refractory disease, as well as a response to gemcitabine, predicted better PFS and OS. Use of a full-dose regimen pre …
A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score.
Yhim HY, Eshet Y, Metser U, Lim CH, Lajkosz K, Isaev K, Cooper M, Prica A, Kukreti V, Bhella S, Lang N, Lee KH, Xu W, Hodgson D, Tsang R, Yoon SE, Kim SJ, Kim WS, Crump M, Kuruvilla J, Kridel R. Yhim HY, et al. Blood Adv. 2020 Nov 24;4(22):5762-5771. doi: 10.1182/bloodadvances.2020002814. Blood Adv. 2020. PMID: 33216888 Free PMC article.
There are limited data regarding the combined value of the pretransplant Deauville score (DS) from a positron emission tomography scan and clinical risk factors in patients with relapsed/refractory aggressive non-Hodgkin lymphoma (NHL). . …
There are limited data regarding the combined value of the pretransplant Deauville score (DS) from a positron emission tomography sca …
Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
Aurer I, Mitrović Z, Nemet D, Radman I, Sertić D, Serventi-Seiwerth R, Stern-Padovan R, Santek F, Nola M, Mrsić M, Labar B. Aurer I, et al. J Chemother. 2008 Oct;20(5):640-4. doi: 10.1179/joc.2008.20.5.640. J Chemother. 2008. PMID: 19048695 Clinical Trial.
These results were similar to those obtained with IMVP (RR 39%, 2-year OS 23%, 2-year EFS 13%; p=0.355 for RR, 0.275 for OS, 0.668 for EFS). Higher IPI scores and refractoriness to treatment were negative prognostic factors, immunophenotype (B vs. ...
These results were similar to those obtained with IMVP (RR 39%, 2-year OS 23%, 2-year EFS 13%; p=0.355 for RR, 0.275 for OS, 0.668 for EFS). …
Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
Pettengell R, Coiffier B, Egorov A, Singer J, Sivcheva L. Pettengell R, et al. Clin Drug Investig. 2018 Jun;38(6):527-533. doi: 10.1007/s40261-018-0635-3. Clin Drug Investig. 2018. PMID: 29564722 Free PMC article. Clinical Trial.
Prior response to previous therapies did not appear to affect long-term response to pixantrone. CONCLUSIONS: These observations suggest that pixantrone monotherapy in patients with multiply relapsed or refractory aggressive NHL who had received at least two prior therapies …
Prior response to previous therapies did not appear to affect long-term response to pixantrone. CONCLUSIONS: These observations sugge …
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M, Hus I, Puła B, Jurczyszyn A, Chojnacki T, Blajer-Olszewska B, Drozd-Sokołowska J, Raźny M, Romejko-Jarosińska J, Taszner M, Jurczak W. Długosz-Danecka M, et al. Pharmacol Rep. 2019 Jun;71(3):473-477. doi: 10.1016/j.pharep.2019.02.001. Epub 2019 Feb 6. Pharmacol Rep. 2019. PMID: 31003160
In 4 patients (16%) stabilization of disease (SD) during therapy was observed and further 4 patients (16%) progressed during the treatment (PD). ...Most common grade 3-4 AEs were due to hematological toxicity with febrile neutropenia observed in 5 patients (20%). Th …
In 4 patients (16%) stabilization of disease (SD) during therapy was observed and further 4 patients (16%) progressed during the trea …
Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
Tseng YD, Chen YH, Catalano PJ, Ng A. Tseng YD, et al. Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):223-31. doi: 10.1016/j.ijrobp.2014.09.041. Int J Radiat Oncol Biol Phys. 2015. PMID: 25835625
PURPOSE: To evaluate the response rate (RR) and time to local recurrence (TTLR) among patients who received salvage radiation therapy for relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) and investigate whether RR and TTLR differed a …
PURPOSE: To evaluate the response rate (RR) and time to local recurrence (TTLR) among patients who received salvage radiation therapy for re …
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Witzig TE, Tomblyn MB, Misleh JG, Kio EA, Sharkey RM, Wegener WA, Goldenberg DM. Witzig TE, et al. Haematologica. 2014 Nov;99(11):1738-45. doi: 10.3324/haematol.2014.112110. Epub 2014 Aug 22. Haematologica. 2014. PMID: 25150258 Free PMC article. Clinical Trial.
Responses occurred in patients with different lymphoma histologies, treated at different (90)Y dose levels, and with a predicted risk of poor outcome, most importantly including five of the six patients treated with the maximal tolerated dose (2 of whom achieved durable co …
Responses occurred in patients with different lymphoma histologies, treated at different (90)Y dose levels, and with a predicted risk …
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pettengell R, et al. Lancet Oncol. 2012 Jul;13(7):696-706. doi: 10.1016/S1470-2045(12)70212-7. Epub 2012 May 30. Lancet Oncol. 2012. PMID: 22652183 Clinical Trial.
We aimed to assess the efficacy and safety of pixantrone versus an investigator's choice of a single-agent therapy in heavily pretreated patients with relapsed or refractory aggressive non-Hodgkin lymphoma. METHODS: In this phase 3, multicentre, …
We aimed to assess the efficacy and safety of pixantrone versus an investigator's choice of a single-agent therapy in heavily pretreated pat …
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC, Qin J, Lyons NC, Yahalom J, Nimer SD, Moskowitz CH. Kewalramani T, et al. Blood. 2000 Oct 1;96(7):2399-404. Blood. 2000. PMID: 11001890 Free article.
Among 42 patients who underwent transplantation, the 3-year overall and event-free survival rates were 52.5% and 44.2%, respectively, similar to the outcomes for patients with chemosensitive relapsed disease. No differences were observed between the IPR and IF groups, and …
Among 42 patients who underwent transplantation, the 3-year overall and event-free survival rates were 52.5% and 44.2%, respectively, simila …
Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
Kancherla RR, Nair JS, Ahmed T, Durrani H, Seiter K, Mannancheril A, Tse-Dinh YC. Kancherla RR, et al. Cancer. 2001 Feb 1;91(3):463-71. doi: 10.1002/1097-0142(20010201)91:3<463::aid-cncr1023>3.0.co;2-r. Cancer. 2001. PMID: 11169927 Clinical Trial.
The authors report Phase I data of topotecan and etoposide combination for patients with recurrent or refractory non-Hodgkin lymphoma and correlation of topoisomerase-DNA complex formation to clinical response. METHODS: Twenty-two patients with recurrent or refractory a …
The authors report Phase I data of topotecan and etoposide combination for patients with recurrent or refractory non-Hodgkin lymphoma and co …
14 results